Страна: САЩ
Език: английски
Източник: NLM (National Library of Medicine)
HYDROCORTISONE BUTYRATE (UNII: 05RMF7YPWN) (HYDROCORTISONE - UNII:WI4X0X7BPJ)
Bausch Health US, LLC
HYDROCORTISONE BUTYRATE
HYDROCORTISONE BUTYRATE 1 mg in 1 g
TOPICAL
PRESCRIPTION DRUG
LOCOID (hydrocortisone butyrate) cream, 0.1% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. None.
LOCOID® (hydrocortisone butyrate) cream, 0.1% is supplied in tubes containing: NDC 16781-382-15 15 g tube NDC 16781-382-45 45 g tube
New Drug Application
LOCOID- HYDROCORTISONE BUTYRATE CREAM BAUSCH HEALTH US, LLC ---------- LOCOID (HYDROCORTISONE BUTYRATE) CREAM, 0.1% FOR TOPICAL USE ONLY NOT FOR OPHTHALMIC USE DESCRIPTION LOCOID (hydrocortisone butyrate) cream, 0.1% contains the topical corticosteroid, hydrocortisone butyrate, a non-fluorinated hydrocortisone ester. It has the chemical name: 11ß,17,21-Trihydroxypregn-4-ene-3,20-dione 17-butyrate; the molecular formula: C H O ; the molecular weight: 432.54; and the CAS registry number: 13609-67-1. Its structural formula is: Each gram of LOCOID cream contains 1 mg of hydrocortisone butyrate in a hydrophilic base consisting of anhydrous citric acid, ceteth-20, cetostearyl alcohol, light mineral oil, propylparaben and butylparaben (preservatives), purified water, sodium citrate, and white petrolatum. CLINICAL PHARMACOLOGY Topical corticosteroids share anti-inflammatory, anti-pruritic, and vasoconstrictive actions. The mechanism of anti-inflammatory activity of topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man. ® ® 25 36 6 PHARMACOKINETICS The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily i Прочетете целия документ